Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

78.04B

Market cap78.04B

Price-Earnings ratio

18.45

Price-Earnings ratio18.45

Dividend yield

0.50%

Dividend yield0.50%

Average volume

738.63K

Average volume738.63K

High today

$757.97

High today$757.97

Low today

$745.67

Low today$745.67

Open price

$749.80

Open price$749.80

Volume

24.48K

Volume24.48K

52 Week high

$859.34

52 Week high$859.34

52 Week low

$541.00

52 Week low$541.00

Stock Snapshot

The current Regeneron(REGN) stock price is $757.97, with a market capitalization of 78.04B. The stock trades at a price-to-earnings (P/E) ratio of 18.45 and offers a dividend yield of 0.50%.

During the trading session on 2026-10-12, Regeneron(REGN) shares reached a daily high of $757.97 and a low of $745.67. At a current price of $757.97, the stock is +1.6% higher than the low and still 0.0% under the high.

Trading volume for Regeneron(REGN) stock has reached 24.48K, versus its average volume of 738.63K.

Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $859.34 and a low of $541.00.

REGN News

TipRanks 3h

Regeneron price target raised to $908 from $891 at BofA

BofA raised the firm’s price target on Regeneron (REGN) to $908 from $891 and keeps a Buy rating on the shares after updating estimates ahead of the company’s Q...

Simply Wall St 13h

Should Alliance Expansion Require Action From Regeneron Investors?

Regeneron Pharmaceuticals expanded its long running alliance with Sanofi, securing a US$1b upfront payment and sharing rights to four new long acting immunology...

Simply Wall St 2d

Regeneron Pharmaceuticals Gets A Fresh Look As Trial Wins And Sanofi Deal Feed Value Narrative

Regeneron Pharmaceuticals (REGN) has landed a cluster of high profile updates in October 2026, from early ubamatamab and trevogrumab trial readouts to a larger...

Analyst ratings

63%

of 30 ratings

Buy

63.3%

Hold

30%

Sell

6.7%

More REGN News

TipRanks 4d

Regeneron Advances Pediatric Rare Disease Program With New Phase 3 Garetosmab Study

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. The phase 3 study titled “Phase 3 Evaluation of the Safety, Pharmacokinet...

Simply Wall St 5d

Combination Cancer Trial Might Change The Case For Investing In Biohaven Stock

Biohaven announced that it entered a clinical supply agreement with Regeneron to test BHV-1530 in combination with cemiplimab in patients with solid tumors, wit...

TipRanks 6d

Regeneron, Sanofi deepen antibody collaboration with expanded alliance

The latest announcement is out from Regeneron ( (REGN) ). On October 1, 2026, Regeneron and long-time partner Sanofi expanded their antibody collaboration thro...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.